2型糖尿病心血管结局试验中普遍和 incident 心力衰竭
本文系统综述了截至2017年6月已发表的降糖药物心血管结局试验,共纳入21项试验、152737例患者。结果发现基线心衰和 incident 心衰的定义与报告不一致,仅部分试验提供心衰住院数据,且仅2项将心衰相关事件纳入主要复合终点。文章强调需改进心衰数据的系统采集。
要点
- 降糖药物心血管结局试验中心衰数据报告不一致,基线心衰定义和 incident 心衰定义不统一。
- 仅3项研究提供基线射血分数数据,且非心衰患者特异性。
- 仅2项试验将心衰相关事件纳入主要复合终点。
核心结论
- 系统综述揭示降糖药物心血管结局试验中心衰数据采集存在显著缺口,需改进心衰表征策略。
研究设计与样本
- 系统综述纳入截至2017年6月发表的21项大型(n>1000)III期和IV期心血管结局试验,共152737例患者。
主要发现
- 基线心衰和 incident 心衰的发生率及定义报告不一致。
- 基线射血分数数据仅3项研究提供,且非心衰患者特异性。
- 无试验报告 incident 心衰诊断时的功能分级、射血分数或心衰治疗。
- 心衰住院数据在15项试验中可获取,但仅2项将心衰相关事件纳入主要复合终点。
临床怎么用
- 临床解读降糖药物心血管结局试验时需注意心衰数据的不一致性,谨慎评估心衰风险。
局限性
- 仅纳入截至2017年6月发表的试验,未涵盖后续研究。
- 数据来源于出版物、FDA咨询委员会记录和FDA标签文件,可能存在报告不全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite multiple examples of glucose-lowering therapies affecting heart failure (HF) risk, ascertainment of HF data in cardiovascular outcome trials of these medications has not been systematically characterized. In this review, large (n >1,000) published phase III and IV cardiovascular outcome trials evaluating glucose-lowering therapies through June 2017 were identified. Data were abstracted from publications, U.S. Food and Drug Administration advisory committee records, and U.S. Food and Drug Administration labeling documents. Overall, 21 trials including 152,737 patients were evaluated. Rates and definitions of baseline HF and incident HF were inconsistently provided. Baseline ejection fraction data were provided in 3 studies but not specific to patients with HF. No trial reported functional class, ejection fraction, or HF therapy at the time of incident HF diagnosis. HF hospitalization data were available in 15 trials, but only 2 included HF-related events within the primary composite endpoint. This systematic review highlights gaps in HF data capture within cardiovascular outcome trials of glucose-lowering therapies and outlines rationale and strategies for improving HF characterization.
引用
- Greene SJ, Vaduganathan M, Khan MS, et al. Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. J Am Coll Cardiol. 2018. PMID: 29534825. doi:10.1016/j.jacc.2018.01.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。